The management of depression: the implications for managed care--roundtable discussion: Part 3.
From the standpoint of managed care, the rising cost of depression can be addressed in multiple ways. In the final portion of the roundtable discussion, the faculty discuss not only disease management programs for depression, but other initiatives health plans (including at the pharmacy level) are undertaking to address the rising costs associated with depression. They also discuss the effect of mental health coverage "parity" laws, which can be expected to drive costs even higher.
Vodoor
M
M
Southwell
Y P
YP
Grubin
M
M
Wert
S
S
Kang-Cipolla
L
L
Denes
A
A
Evans
S
S
Mason
J
J
Zarr
M
M
Osborn
L
L
Kenney
J
J
Hunkeler
E
E
Waugh
W
W
Bull
S
S
D000928:Antidepressive Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003866:Depressive Disorder / Q000188:drug therapy / Q000191:economics*; D019468:Disease Management; D005569:Formularies as Topic; D006264:Health Benefit Plans, Employee / Q000592:standards; D006801:Humans; D008329:Managed Care Programs / Q000458:organization & administration*; D008605:Mental Health Services / Q000458:organization & administration*; D017410:Practice Guidelines as Topic; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics / Q000627:therapeutic use*
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors